Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Discovery Labs Raises $12.8M Privately To Progress Surfaxin

Nov. 7, 2002

By Aaron Lorenzo

Isis Gets Rights To ISIS 14803 Back From Elan Joint Venture

Nov. 7, 2002

By Aaron Lorenzo

Discovery Labs Raises $12.8M Privately To Progress Surfaxin

Nov. 7, 2002

By Aaron Lorenzo

GeoVax Prepares For Trials Of AIDS Vaccine Candidate

Nov. 6, 2002

By Aaron Lorenzo

GeoVax Prepares For Trials Of AIDS Vaccine Candidate

Nov. 6, 2002

By Aaron Lorenzo

Alexion Data Point To Potential For Treatment Over Long Term

Nov. 5, 2002

By Aaron Lorenzo

Alexion Data Point To Potential For Treatment Over Long Term

Nov. 5, 2002

By Aaron Lorenzo

Cerus Gets $50M Loan Pledge From Intercept Partner Baxter

Nov. 1, 2002

By Aaron Lorenzo

Cerus Gets $50M Loan Pledge From Intercept Partner Baxter

Nov. 1, 2002

By Aaron Lorenzo

Neurogenetics Closes Series B With Second Tranche Of $10M

Oct. 31, 2002

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...